Collegium Pharmaceutical (COLL) Q4 2024: Jornay PM Prescriptions Surge 29%, Paving Way for 34% Revenue Growth in 2025
Collegium Pharmaceutical demonstrated strong momentum in its neuropsychiatry and pain portfolios, driven by robust growth in Jornay PM prescriptions and record revenues in core pain products. The company’s strategic acquisition and disciplined capital deployment underpin a confident outlook for accelerated growth and margin expansion starting in 2026. Targeted investments in Jornay PM’s commercial infrastructure set the stage for sustained market penetration and shareholder value creation.
Summary
- Jornay PM Momentum: Accelerated prescription growth signals successful integration and positions the brand as the primary growth engine.
- Durable Pain Portfolio: Record revenues and extended exclusivity reinforce a stable cash flow foundation supporting reinvestment.
- Strategic Capital Deployment: Focus on salesforce expansion, share repurchases, and debt reduction underpins financial strength and growth trajectory.
Business Overview
Collegium Pharmaceutical is a diversified biopharmaceutical company specializing in responsible pain management and neuropsychiatry treatments. The company generates revenue primarily through its branded pharmaceutical products, including its pain portfolio (Belbuca, Xtampza ER, and Nucynta ER) and the recently acquired neuropsychiatric medication Jornay PM, which treats attention deficit hyperactivity disorder (ADHD). The firm’s business model emphasizes commercial execution, strategic acquisitions, and disciplined capital allocation to drive growth and shareholder value.
Performance Analysis
In the fourth quarter of 2024, Collegium delivered record net product revenues of $181.9 million, representing a 22% year-over-year increase, driven notably by the first full quarter of Jornay PM ownership. On a pro forma basis, full-year 2024 Jornay PM net revenues reached $100.7 million and are forecasted to exceed $135 million in 2025, reflecting over 34% growth. The pain portfolio remained a robust contributor, with Belbuca and Xtampza ER achieving record quarterly revenues of $55.2 million and $51.5 million, respectively, supported by sustained prescription growth.
Adjusted EBITDA increased 3% year-over-year to $107.7 million in the quarter, and 9% for the full year to $401.2 million, underscoring operational leverage despite front-loaded investments. GAAP operating expenses rose substantially due to integration and growth initiatives, with adjusted operating expenses nearly doubling year-over-year in the quarter to $51.1 million. The company’s net leverage improved to below two times net debt over adjusted EBITDA exiting 2024, with expectations to reduce to less than one time by year-end 2025.
- Prescription Growth Drivers: Jornay PM prescriptions surged 29% year-over-year and 11% quarter-over-quarter in Q4, while Belbuca prescriptions grew 5.6% year-over-year, reinforcing strong commercial execution.
- Exclusivity Extensions: Nucynta franchise exclusivity extended to mid-2027, enhancing revenue durability and mitigating generic risk near term.
- Capital Deployment: $60 million in share repurchases and $200 million acquisition investment demonstrate disciplined financial strategy supporting growth and shareholder returns.
Overall, Collegium’s financial performance reflects successful integration of Iron Shore Therapeutics, solid execution in its pain portfolio, and strategic positioning for accelerated growth driven by Jornay PM. The company’s investment in salesforce expansion and marketing initiatives is expected to amplify growth momentum into 2026 and beyond.
Executive Commentary
"2024 was a year of strong execution for Collegium, marked by robust performance in our pain portfolio and the addition of Jornay PM, establishing our presence in neuropsychiatry and reaffirming our commitment to helping improve the lives of people living with serious medical conditions. This was made possible thanks to the dedication of our talented team."
Vikram Karnani, President and Chief Executive Officer
"We are proud to have delivered on our financial commitments and strategic priorities for 2024, including growing total revenue by 11% and adjusted EBITDA by 9%, generating robust operating cash flows in a year that we completed an acquisition, and deploying capital to expand and diversify our business while executing $60 million in share repurchases."
Colleen Tupper, Chief Financial Officer
Strategic Positioning
1. Accelerating Jornay PM Growth Through Targeted Commercial Investments
Collegium is expanding its salesforce from approximately 125 to 180 representatives to increase coverage of the ADHD prescriber base, targeting around 60% of the long-acting stimulant market. Complementary digital marketing efforts aimed at patients and caregivers are designed to raise brand awareness and drive demand. These investments, front-loaded in 2025, are expected to yield majority impact in 2026 and beyond, positioning Jornay PM as the company’s lead growth driver.
2. Maximizing Pain Portfolio Revenue Durability and Market Position
The company’s pain portfolio, including Belbuca and Xtampza ER, delivered record revenues supported by steady prescription growth and successful payer strategies. Extensions of exclusivity for Nucynta ER and IR through mid-2027, alongside authorized generic agreements, reinforce the portfolio’s revenue resilience. Collegium emphasizes educating physicians on product differentiation and abuse deterrent properties to sustain and grow utilization.
3. Disciplined Capital Allocation to Enhance Financial Strength
Collegium’s capital deployment strategy balances growth investments with shareholder returns and debt reduction. The company repurchased $60 million in shares during 2024 and plans to continue opportunistic buybacks with $90 million remaining authorized through mid-2025. Net leverage is expected to decline below one time by the end of 2025, reflecting robust cash flow generation and prudent financial management.
4. Strategic Business Development Focused on Adjacent and Capital-Efficient Assets
Management prioritizes acquisitions of commercial assets that complement the ADHD and neuropsychiatry focus, as well as capital-efficient opportunities in rare or orphan diseases. The company’s strong financial position supports active portfolio expansion, but with a disciplined approach ensuring strategic and financial fit.
5. Enhancing Corporate Governance and Investor Relations
The appointment of Nancy Lurker, an experienced biopharmaceutical executive, to the board strengthens Collegium’s governance and commercial expertise. The addition of a new head of investor relations reflects a commitment to transparent communication and shareholder engagement during this growth phase.
Key Considerations
Collegium’s Q4 and full-year 2024 results highlight a company at an inflection point, balancing integration and growth investments with financial discipline. Key considerations include:
- Salesforce Expansion Impact: The increase in sales representatives aims to capture a larger share of a concentrated ADHD prescriber base, critical to unlocking Jornay PM’s growth potential.
- Exclusivity and Generic Risk Management: Extended patent protection and regulatory barriers mitigate near-term generic competition risks, particularly for the Nucynta franchise.
- Investment Timing and Margin Pressure: Front-loaded marketing and sales investments in 2025 will temporarily pressure margins but are expected to drive improved adjusted EBITDA margins starting in 2026.
- Market Dynamics in ADHD and Pain: The ADHD stimulant market’s growth and prescriber concentration offer opportunities, while the pain portfolio faces typical first-quarter prescription headwinds due to deductible resets and formulary changes.
- Capital Deployment Flexibility: The company’s strong cash position and leverage reduction plans provide flexibility for opportunistic acquisitions and shareholder returns.
Risks
Collegium faces risks common to specialty pharmaceutical companies, including potential market access challenges, regulatory scrutiny, and litigation related to opioid products. The timing and impact of generic competition remain uncertain despite exclusivity extensions. Additionally, increased investments in Jornay PM may not yield anticipated returns within expected timeframes, and broader healthcare reimbursement dynamics could affect revenue growth.
Forward Outlook
For the first quarter of 2025, Collegium anticipates typical seasonal revenue softness due to deductible resets and formulary changes, particularly impacting the pain portfolio. The company reaffirmed full-year 2025 guidance with:
- Net product revenues expected between $735 million and $750 million, driven primarily by Jornay PM exceeding $135 million.
- Adjusted operating expenses forecasted at $220 million to $230 million, reflecting increased commercial investments.
- Adjusted EBITDA projected between $435 million and $450 million, representing over 10% growth year-over-year.
Management emphasized that commercial initiatives and salesforce expansion will be front-loaded in the first half of 2025, with margin improvement expected beginning in 2026.
Takeaways
Collegium Pharmaceutical is transitioning from a strong legacy pain franchise toward a more diversified biopharmaceutical company with a growing neuropsychiatry presence. Key takeaways include:
- Jornay PM as a Growth Catalyst: The brand’s rapid prescription growth and planned commercial investments signal a clear inflection in Collegium’s revenue trajectory, with potential to reshape its product mix.
- Robust Pain Portfolio Stability: Continued prescription growth and exclusivity extensions underpin a dependable cash flow base that supports strategic investments and capital returns.
- Financial Discipline Enables Strategic Flexibility: Strong leverage metrics and cash flow generation provide the company with the capacity to pursue acquisitions, invest in growth, and return capital to shareholders.
Conclusion
Collegium Pharmaceutical’s fourth quarter and full-year 2024 results reflect successful integration of Jornay PM and strong execution across its pain portfolio. The company’s strategic focus on commercial investment, capital discipline, and portfolio expansion positions it for accelerated growth and improved margins starting in 2026. Investors should monitor the impact of salesforce expansion and marketing initiatives on Jornay PM adoption as key indicators of future performance.
Industry Read-Through
Collegium’s progress in integrating a neuropsychiatry asset alongside a mature pain portfolio exemplifies a broader industry trend of biopharmaceutical companies diversifying to reduce reliance on opioid-related revenues. The company’s emphasis on salesforce optimization and targeted digital marketing reflects evolving commercial strategies in specialty pharmaceuticals, particularly in ADHD treatment where prescriber concentration enables focused outreach. The extended exclusivity achievements underscore the importance of patent and regulatory strategies in managing generic risk. Other companies in pain management and neuropsychiatry should watch for how disciplined capital deployment and portfolio diversification support sustainable growth amid regulatory and market pressures.